title: [Modification of coronary arteriosclerosis in man by calcium antagonists?].
abstract: Calcium channel blockers may retard development and progression of coronary arteriosclerosis in man because of protective effects on membranes, (especially the endothelium), relaxation of vessel walls, inhibition of various platelet functions, impairment of proliferation and migration of smooth muscle cells in the vessel wall, and an improvement of vascular cholesterol metabolism. In animal trials development of atheromas in large arteries induced by cholesterol-rich food and other stimuli of atherogenesis could be successfully retarded by a broad variety of calcium channel blockers. Some clinical observations in patients with coronary artery disease pointed at positive effects of calcium antagonists in coronary arteriosclerosis. To date, the results of three prospective placebo-controlled trials with calcium antagonists in coronary arteriosclerosis are available. In all trials progression of atherosclerosis was assessed by serial angiograms: 1) INTACT (nifedipine: 20 mg four times daily; observation period: 3 years, two coronary angiograms); 2) Study of the Montreal Heart Institute (nicardipine: 30 mg three times daily; observation period: 2 years, two coronary angiograms); 3) FIPS (Frankfurt Isoptin Progression Study) (verapamil: 120 mg three times daily; observation period: 3 years, three coronary angiograms). Target variables in these studies were progression or regression of preexisting lesions, development of new lesions and the incidence of vessel occlusions. The INTACT and the Nicardipine studies preferably included patients in early stages of coronary artery disease. The patients of FIPS who were entered into the study immediately after coronary bypass surgery suffered from severe, advanced coronary artery disease. In the latter study progression of coronary artery disease was assessed separately in different vascular regions (bypassed and non-bypassed segments) and in the bypass grafts.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Abteilung für Kardiologie, J. W. Goethe-Universität, Frankfurt a.M.
authors.forename: W
authors.initials: W
authors.lastname: Schneider
authors.forename: P
authors.initials: P
authors.lastname: Roebruck
authors.forename: G
authors.initials: G
authors.lastname: Cieslinski
authors.forename: H
authors.initials: H
authors.lastname: Noack
authors.forename: G
authors.initials: G
authors.lastname: Kober
authors.forename: M
authors.initials: M
authors.lastname: Alle
authors.forename: M
authors.initials: M
authors.lastname: Kaltenbach
mesh_terms: D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000401:mortality; D003326:Coronary Circulation / Q000187:drug effects; D006801:Humans; D015996:Survival Rate
chemical_list: D002121:Calcium Channel Blockers
vernacular_title: Beeinflussung der Koronarsklerose des Menschen durch Kalziumantagonisten?